HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (2000)].

Abstract
From October 2000 to September 2001, we collected the specimen from 410 patients with lower respiratory tract infections in 16 institutions in Japan, and investigated the susceptibilities of isolated bacteria to various anti-bacterial agents and antibiotics and patients' characteristics. Of 499 strains that were isolated from specimen (mainly from sputum) and assumed to be bacteria causing in inflammation, 493 strains were investigated. The breakdown of the isolated bacteria were: Staphylococcus aureus 78, Streptococcus pneumoniae 73, Haemophilus infiuenzae 99, Pseudomonas aeruginosa (non-mucoid) 64, P. aeruginosa (mucoid) 14, Klebsiella pneumoniae 25, Moraxella subgenus Branhamella catarrhalis 21, etc. Of 78 S. aureus strains, those with 4 micrograms/ml or more of MIC of oxacillin (methicillin-resistant S. aureus: MRSA) occupied 53.8%. Vancomycin and arbekacin had the most potent activities against MRSA as observed in 1999. The frequency of S. pneumoniae exhibiting low sensitivity to penicillin (penicillin-intermediate S. pneumoniae: PISP + penicillin-resistant S. pneumoniae: PRSP) was 38.4% being consistent with that in 1999 (34.7%). PRSP accounted for 11.0% of the total, being more than that in 1999 (3.0%). Carbapenems had strong activities against S. pneumoniae. Especially, panipenem inhibited the growth of all 73 strains at 0.125 microgram/ml. Generally, all drugs had strong activities against H. influenzae with MIC80s of 8 micrograms/ml or less. The drug that had the strongest activity against H. infiuenzae was levofloxacin, which inhibited the growth of 94 of the 99 strains at 0.063 microgram/ml. Tobramycin had a strong activity against P. aeruginosa (both mucoid and non-mucoid) with MIC80 of 1 microgram/ml. The mucoid strain was little isolated (14 strains) but the susceptibilities to all drugs were better than the non-mucoid strain. K. pneumoniae showed good susceptibilities to all drugs except ampicillin and the MIC80S were 2 micrograms/ml or less. Particularly, cefpirome, cefozopran, and levofloxacin had strong bactericidal activities against K. pneumoniae with MIC80s of 0.125 microgram/ml, and cefotiam, second-generation cephems, also had a favorable activity being MIC80 of 0.25 microgram/ml. Also, all drugs generally had strong activities against M. (B.) catarrhalis. MIC80s of all drugs were 2 micrograms/ml or less. The drug having the strongest activity was imipenem and levofloxacin inhibiting all 21 strains at 0.063 microgram/ml. Most of the patients with respiratory infection were aged 70 years or older, accounting for approximately a half of the total (44.4%). As for the incidence by the diseases, bacterial pneumonia and chronic bronchitis were the highest, being noted in 38.0% and 31.7% of all the patients, respectively. The bacteria frequently isolated from the patients with bacterial pneumonia were S. aureus (18.3%) and S. pneumoniae (16.1%). In contrast, H. infiuenzae (20.4%) and P. aeruginosa (both mucoid and non-mucoid: 16.7%) were frequently isolated from the patients with chronic bronchitis. Before the drug administration, the bacteria frequently isolated from all the patients were S. pneumoniae (24.3%) and H. infiuenzae (26.7%). The frequency of isolated S. pneumoniae tended to decrease with the increase in the number of administration days while that of isolated H. infiuenzae did not. The frequency of isolated P. aeruginosa tended to increase with the duration of administration. The isolated bacteria were comparable between the patients already treated with penicillins and cephems. In the patients treated with aminoglycosides, macrolides, and quinolones, P. aeruginosa was most frequently isolated (33.3 to 40.0%).
AuthorsKaoru Shimada, Tsugio Terai, Jun Igari, Hiroshi Inoue, Toshihide Nakadate, Toyoko Oguri, Akira Suwabe, Ritsuko Obata, Hideo Ikemoto, Isao Ohno, Shinji Okada, Katsutoshi Hayashi, Takeshi Mori, Kunio Nakano, Masaaki Arakawa, Fumitake Gejyo, Kenichi Igarashi, Hiroshi Yokouchi, Masahiko Okada, Akira Ito, Midori Sumitomo, Nobuki Aoki, Toshiharu Matsushima, Yoshihito Niki, Nobuko Kitamura, Moritaka Suga, Yasutoshi Suzuki, Yasuo Karasawa, Masakazu Tosaka, Kouichiro Nakata, Tatsuo Nakatani, Shigeru Kohno, Kazunori Tomono, Yoshitsugu Miyazaki, Hiroko Inagawa, Yoichi Hirakata, Shiho Aoki, Junichi Matsuda, Kouichiro Kudo, Nobuyuki Kobayashi, Tadao Kinoshita, Hisami Konosaki, Masaru Nasu, Hiroyuki Nagai, Hiroyuki Kobayashi, Shin Kawai, Satoshi Takayasu, Kazufumi Hiramatsu, Tadao Nakano
JournalThe Japanese journal of antibiotics (Jpn J Antibiot) Vol. 55 Issue 5 Pg. 537-67 (Oct 2002) ISSN: 0368-2781 [Print] Japan
PMID12532637 (Publication Type: Journal Article, Multicenter Study)
Chemical References
  • Anti-Bacterial Agents
Topics
  • Anti-Bacterial Agents (pharmacology)
  • Bacteria (drug effects, isolation & purification)
  • Drug Resistance, Bacterial
  • Haemophilus influenzae (drug effects)
  • Humans
  • Klebsiella pneumoniae (drug effects)
  • Pseudomonas aeruginosa (drug effects)
  • Respiratory Tract Infections (microbiology)
  • Staphylococcus aureus (drug effects)
  • Streptococcus pneumoniae (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: